Cargando…
CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
SIMPLE SUMMARY: CYCLON is a nuclear protein, which has been associated with disease progression and treatment resistance in DLBCL, the most common form of aggressive B-cell lymphoma, but also represents a predictive factor of refractory disease and relapse for immuno-chemotherapy-treated DLBCL patie...
Autores principales: | Bouroumeau, Antonin, Bussot, Lucile, Hamaidia, Sieme, Garcìa-Sandoval, Andrea, Bergan-Dahl, Anna, Betton-Fraisse, Patricia, Duley, Samuel, Fournier, Cyril, Aucagne, Romain, Adrait, Annie, Couté, Yohann, McLeer, Anne, Col, Edwige, David-Boudet, Laurence, Raskovalova, Tatiana, Jacob, Marie-Christine, Vettier, Claire, Chevalier, Simon, Carras, Sylvain, Lefebvre, Christine, Algrin, Caroline, Gressin, Rémy, Callanan, Mary B., Sartelet, Hervé, Bonnefoix, Thierry, Emadali, Anouk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656558/ https://www.ncbi.nlm.nih.gov/pubmed/34885010 http://dx.doi.org/10.3390/cancers13235900 |
Ejemplares similares
-
Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021) -
c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma
por: Bouroumeau, Antonin, et al.
Publicado: (2021) -
Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report
por: Bouroumeau, Antonin, et al.
Publicado: (2020) -
1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma
por: Fournier, Alexandra, et al.
Publicado: (2010) -
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
por: Emadali, Anouk, et al.
Publicado: (2013)